Banque Transatlantique SA Has $4.17 Million Holdings in Solventum Corporation $SOLV

Key Points

• Banque Transatlantique SA significantly increased its stake in Solventum Corporation, raising its holdings by 9,219.8% during Q1, and now owns 59,274 shares valued at approximately $4.17 million.
• Analysts are optimistic about Solventum, with upgrades from notable firms like Morgan Stanley raising the price target from $80 to $103, and a consensus rating of "Hold" with an average target price of $85.75.
• Solventum reported a strong quarterly performance, with EPS of $1.69 surpassing expectations, alongside a revenue of $2.16 billion, while projecting FY 2025 EPS guidance of $5.800-$5.950.

Banque Transatlantique SA raised its holdings in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 9,219.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 59,274 shares of the company's stock after purchasing an additional 58,638 shares during the period. Banque Transatlantique SA's holdings in Solventum were worth $4,165,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Tradition Wealth Management LLC increased its stake in Solventum by 1.6% during the first quarter. Tradition Wealth Management LLC now owns 8,830 shares of the company's stock valued at $671,000 after purchasing an additional 143 shares during the last quarter. Perigon Wealth Management LLC boosted its holdings in shares of Solventum by 3.8% during the first quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company's stock valued at $331,000 after acquiring an additional 159 shares during the period. SouthState Corp boosted its holdings in shares of Solventum by 31.9% during the first quarter. SouthState Corp now owns 699 shares of the company's stock valued at $53,000 after acquiring an additional 169 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Solventum by 22.3% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 937 shares of the company's stock valued at $71,000 after acquiring an additional 171 shares during the period. Finally, EP Wealth Advisors LLC boosted its holdings in shares of Solventum by 3.6% during the fourth quarter. EP Wealth Advisors LLC now owns 5,272 shares of the company's stock valued at $348,000 after acquiring an additional 181 shares during the period.

Solventum Price Performance

SOLV stock traded up $0.32 during trading on Friday, hitting $72.70. The company had a trading volume of 682,814 shares, compared to its average volume of 1,297,940. The firm has a market capitalization of $12.61 billion, a price-to-earnings ratio of 33.66, a P/E/G ratio of 1.76 and a beta of 0.53. The business has a 50 day moving average of $73.53 and a 200 day moving average of $72.76. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $85.92. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. During the same period in the prior year, the company earned $1.56 EPS. Solventum's revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Analysts Set New Price Targets

SOLV has been the subject of several analyst reports. KeyCorp initiated coverage on shares of Solventum in a report on Friday, June 6th. They set a "sector weight" rating for the company. Argus raised shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target for the company in a report on Tuesday, July 1st. Morgan Stanley raised shares of Solventum from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $80.00 to $103.00 in a report on Tuesday, July 15th. Wall Street Zen raised shares of Solventum from a "buy" rating to a "strong-buy" rating in a report on Monday, September 1st. Finally, Wells Fargo & Company boosted their price target on shares of Solventum from $75.00 to $79.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Solventum has an average rating of "Hold" and an average price target of $85.75.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.